SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.06500.0%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jm2i123 who wrote (12276)8/4/2013 1:53:05 PM
From: NTTG1 Recommendation

Recommended By
Pogeu Mahone

  Read Replies (1) of 13111
 
Congratulations to Dr Thompson on his award; his rich publication track record attests to his work, although efforts with PV-10 are barely on his radar in comparison to other more promising interventions he has been involved with.

Home work assignment for you:

What % of DR Thompson's publications or research efforts focus on PV-10 administration?

Why has he switched research direction to limb perfusion administration of V-10 after learning that nodal stage III and stage IV patients will be excluded from the proposed PIII trial? Or, account for his gap in new research on RB between 2009 to 2013?

NO doubt he is an accomplished investigator...but an endorsement of PV-10 seems like a stretch
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News